RWS Half Year Results 2022
9 June 2022
Andrew Brode | Ian El-Mokadem | Rod Day |
Chairman | Chief Executive | Interim Chief |
Officer | Financial Officer |
2 © 2022 RWS
Agenda
Overview
Financial Review
Strategic and Operational Review
Current Trading and Outlook
Appendix
3 © 2022 RWS
Unique, world-leading provider of technology-enabled language, content and IP services
Revenue¹ | Adjusted PBT¹ | Expertise | Reach | |||
2003 | £27m | 2003 | £6m | |
2005 | £36m | 2005 | £7m | |
2007 | £46m | 2007 | £11m | |
2009 | £56m | 2009 | £15m | |
2011 | £65m | 2011 | £16m | |
2013 | £77m | 2013 | £21m | |
2015 | £95m | 2015 | £23m | |
2017 | £164m | 2017 | £43m | |
2019 | £356m | 2019 | £74m | |
2021 | £695m | 2021 | £116m | |
2003 | 2003 |
400
2022 | 2022 |
7,796²
Long track record of sustained growth and customer delivery
4 © 2022 RWS | Notes: ¹ - RWS 2021 Annual Report; ² - FTE at 31 March 2022 |
High quality, long-term client relationships
Supporting our ability to grow organically on a sustainable basis
- Diversified client base:
- Top 10 = 30% Group revenues
- Top 30 = 41% Group revenues
- High loyalty - average tenure:
- 16 years (Top 10)
- 13 years (Top 30)
- Revenue growth (CAGR 2017-2021):
- Top 10 = 7.5%
- Top 30 = 7.7%
- High satisfaction
- +41 NPS (12 month rolling average)
90 of the | 16 of | |
Fortune's | 20 of the | |
top 100 | top 20 | top 20 |
most | pharma | |
brands | ||
admired | companies | |
companies |
Major | 19 of the |
top 20 | |
global | |
medical | |
technology | |
device | |
businesses | |
companies | |
19 of the | 18 of the | 10 of the |
top 20 | ||
top 20 | top 10 | |
patent | ||
law firms | insurers | |
filers | ||
5 © 2022 RWS | Note: revenue and tenure data at 30 Sept 2021; NPS = 12 months to 30 Apr 2022 |
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
RWS Holdings plc published this content on 09 June 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 June 2022 07:51:06 UTC.